GSK spun out DDXS. I don't think they are going to want it back. But there are a number of larger diagnostic companies that could fold DDXS in. That makes more sense than GSK getting into the testing business.
1.50 could never be a good entry point. We will have Darap news before it has time to sink to $1.50. If Darap is positive, we'll never see $1.50 again. If Darap is negative, well... I think it goes back to a buck. Either way, waiting for $1.50 is about the dumbest idea possible.
The management was positively giddy on the call. They are rolling in the dough now and the future is evern brighter. It is shining through. Naturally, I hope they keep it rolling, but boy, if they stumble, there is going to be quite a bit of schadenfreude for the management and the stockholders.
If you are telling the truth, this is going to be the coolest message board event ever.
This is one strong stock. I think it is a little toppy here, but I thought that at 50. CBST has long been a takeover candidate. The stock trades like something is imminent; yet, it makes no sense. CBST still has a lot of digesting of its own acquisitions to do.
When a stock moves like this, you are going to find people willing to sell. Point is that there are buyers taking down size. Wow.
The only negative is the wait. I think Stimuvax is dead, not because the data sucked, it was ok, but because OM-10 is better. Merck and Onty know it. If they are going to start from scratch, might as well do it with the better drug. This of course adds to the wait.
Did it again. Tenofovir Alafenamide (TAF) is a hit. 1/10 the drug works just as well as the original. Patent expiration... no problem. In fact, when was the last time anybody mentioned the "Patent Cliff?"
What's the story with the thumb downs? Is there one joker out there who thinks he is funny having two dozen yahoo IDs?
That said... any solid speculation on what is driving the move today?